- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Resource Utilization in Patients with Bisphosphonate - Associated Osteonecrosis of the Jaw | ||
| MUSTANSIRIA DENTAL JOURNAL | ||
| Article 1, Volume 9, Issue 2, 2012, Pages 218-228 | ||
| Authors | ||
| ; ; Dr. Hajer Ibrahem; ; ; ; Dr. Mohammed Suhail Najm; ; Dr. Nathaniel S. Treister; ; ; ; ; ; Dr. Daniel H. Solomon | ||
| Abstract | ||
| Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is an emerging oral complication that occur secondary to cancer therapy in approximately 5% of cancer patients that are treated with high dosages of intravenous (IV) bisphosphonates and can be associated with significant health-care associated costs. A retrospective electronic medical record based on review of ninety-four cancer patients with BONJ. All health care related resources were abstracted using a structured chart abstraction tool, including medications, imaging, pathology, procedures, and visits. Standardized references were used to assign costs. The median cost of a case of BONJ in our cohort was $1,546 (interquartile range from $869-$3,166). Medication costs comprise 48%, visits 23%, procedures 16%, imaging 10% and pathology 2%. The major contributing factors that affect BONJ treatment cost were long term medication and follow up visits Long term medication, sequestrectomy and debridement are a bit expensive but could be a part of evidence-based successful clinical outcome. The cost of BONJ treatment is modest compared with the cost of cancer care. | ||
| Keywords | ||
| Key Words; Bisphosphonates; BONJ; Cancer; cost | ||
|
Statistics Article View: 131 PDF Download: 55 |
||